CSM recommendations

Last reviewed 01/2018

Prolonged use of cyproterone may produce dose-related hepatotoxicity. Effects include:

• hepatitis
• cholestatic jaundice
• hepatic failure
• death

The Committee on the Safety of Medicine recommend that:

• long-term daily doses of 300 mg be restricted to:
• short courses to cover the effects of LHRH agonists or following orchidectomy
• patients who fail to respond to, or cannot tolerate, alternative treatments
• liver function tests are conducted before treatment and whenever hepatic impairment is suspected
• cyproterone is withheld once evidence of hepatotoxicity develops